Salt Lake City, United States
Myriad Genetics, founded in 1991 and headquartered in the United States, is a prominent player in the field of molecular diagnostic testing and precision medicine. The company is committed to advancing health and well-being through its innovative tests, which assess disease risk and guide treatment decisions, thereby improving patient care and reducing healthcare costs.
This commitment aligns with Myriad Genetics's slogan: "Leading molecular diagnostic testing & precision medicine company dedicated to advancing health and well-being for all." The company has shown a steady trajectory of growth and innovation in a rapidly evolving medical landscape.
Recently, Myriad Genetics secured a $125.00M Post IPO Debt investment on 01 July 2025, with investment from OrbiMed. This infusion of capital is poised to further bolster the company's capacity to innovate and expand its molecular diagnostic offerings across various medical specialties. For potential investors, Myriad Genetics presents a compelling opportunity at the intersection of healthcare advancement and cost-effectiveness.
